Sotera Health Company (SHC) has a MoatMap StockRank of 71/100 based on Quality (63/100), Value (33/100), and Momentum (60/100) factor scores. The current signal is BUY. Sotera Health operates a near-monopoly in medical device and pharmaceutical sterilization services, a critical bottleneck in the healthcare supply chain. This aligns with our CDMO pricing power and localization themes, as sterilization cannot be easily bypassed or offshored. However, persistent regulatory scrutiny and past litigation regarding ethylene oxide emissions act as a capital overhang, preventing a high-conviction buy despite the high-moat business model.
Sotera Health Company is a leading global provider of mission-critical sterilization and lab testing services for the medical device, pharmaceutical, and food industries. The company ensures product safety and integrity through its specialized sterilization and analytical services, leveraging extensive regulatory expertise and a global network of facilities. Its indispensable role in the healthcare supply chain, combined with high barriers to entry, provides a significant and defensible market position.
| Price | $16.53 |
| Market Cap | $4.5B |
| P/E (TTM) | 37.98 |
| P/E (Forward) | 14.69 |
| Price/Book | 7.13 |
| Return on Equity | 22.7% |
| Return on Invested Capital | 10.1% |
| Debt/Equity | 364.72 |
| Gross Margin | 55.3% |
| Operating Margin | 31.3% |
| Revenue Growth | 10.0% |
| Free Cash Flow | $145M |
Sotera Health Company operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).